Recent Patents on Nanotechnology最新文献

{"title":"Progress on One-dimensional Vanadium Pentoxide-based Nanomaterials for Advanced Energy Storage ANSTEEL Research Institute of Vanadium & Titanium (Iron & Steel), China.","authors":"Wei Ni","doi":"10.2174/0118722105349485241028104311","DOIUrl":"https://doi.org/10.2174/0118722105349485241028104311","url":null,"abstract":"<p><p>One-dimensional (1D) vanadium-based nanostructures have advantageous properties and are showing emerging critical applications in the fields of catalysis, smart devices, and electrochemical energy storage. We herein timely gave an overview of the 1D vanadium pentoxide (V₂O₅)-based nanomaterials for these promising applications, especially regarding the merits of different synthetic methods, structures and properties combined with recent research frontiers in advanced energy storage, including batteries, supercapacitors and like. The high capacity, high rate and flexibility of 1D V₂O₅-based nanomaterials endow them with great potential in high-energy-density, high-power energy devices and specific/harsh environments. Finally, the directions and suggestions are provided for further development of this emerging and promising field.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic Field Modulation Effect of Photoelectric Properties in Dye-sensitized Solar Cells with La_0.67(Ca,Ba)_0.33MnO₃ as Counter Electrodes.","authors":"Guanzhong Huo, Wenqing Lin, Ke Wang, Zhe Pei, Xuan Du, Shuiyuan Chen, Chao Su, Qingying Ye, Guilin Chen","doi":"10.2174/1872210518666230915142211","DOIUrl":"10.2174/1872210518666230915142211","url":null,"abstract":"<p><strong>Background: </strong>In recent years, many semiconductor materials with unique band structures have been used and also pursued patent protection as Pt counter electrode (CE) substitutes for dyesensitized solar cells (DSSCs), which makes the photoelectric properties of DSSCs possible to be modulated by electric field, magnetic field, and light field. In this work, La_0.67(Ca,Ba)_0.33MnO₃ (LCBMO) thin film is employed to act as CE in DSSCs.</p><p><strong>Methods: </strong>The experimental results indicate that short-circuit current density and photoelectric conversion efficiency present better stability when applying an external magnetic field to the DSSCs. Furthermore, both the exchange current density (J₀) and limit diffusion current density (J_lim) are largely enhanced by an external magnetic field. J₀ increases from -0.51 mA·cm^-2 to -0.65 mA·cm^-2, and J_lim increases from 0.2 mA·cm^-2 to 0.3 mA·cm^-2 when applying a magnetic field of 0.25 T.</p><p><strong>Results: </strong>The fitting results of the impedance test verify that the magnetic field reduces the value of R_ct.</p><p><strong>Conclusion: </strong>Both magnetic-field enhancing catalytic activity and CMR effect jointly promote the increase of photocurrent and finally improve the photovoltaic effect in DSSCs.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":"140-147"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10339078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review and Meta-Analysis of the Metal Nano-Particles Loaded with Herbal Drugs Moieties Against Breast Cancer.","authors":"Suchitra Nishal, Virender Kumar, Parmita Phaugat, Davinder Kumar, Naveen Khatri, Gajendra Singh","doi":"10.2174/1872210518666230907115056","DOIUrl":"10.2174/1872210518666230907115056","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most prevalent cancer among women. About 685K deaths were globally listed in 2020 by the World Health Organization. Nowadays, scientists prefer to use herbal medicines due to their low toxicity. Herbal medicines are used to overcome the toxicity effects of surgical removal, radio-chemo therapy and medication, which have a lot of risk of damaging the healthy tissues. To overcome this, enhance bioavailability and target specify, nano-formulation chemotherapy was introduced using herbal moiety for anticancer activity. The use of metallic nanoparticles (MNPs), particularly those made of silver, cobalt, zinc, and gold as contrast, antibacterial, anticancer, and drug delivery agents has revolutionised the medicinal field. Although MNPs can be made via exacting physical and chemical processes, a biological method utilising natural materials has been established recently.</p><p><strong>Objectives: </strong>This patent review article will offer a succinct explanation of the use of MNPs and its potential impact on herbal medicines in the future.</p><p><strong>Methods: </strong>Using PRISMA principles, this review systematically examines studies that concentrate on metal nanoparticles loaded with herbal compounds for the treatment of breast cancer. Various Databases were studied: PubMed, Elsevier, ScienceDirect, SpringerLink, Taylor & Francis Online, ACS Publications, Publishing Royal Society of Chemistry, and Future Medicines. Studies were selected if they were peer-reviewed primary studies published in the past 10 years.</p><p><strong>Results: </strong>We found that many herbal nano-formulations are more effective in breast cancer treatment than other types of formulations. Efficacy, safety and drug stability are also enhanced using nanoformulations.</p><p><strong>Conclusion: </strong>Nano-formulation is found to be more effective in the treatment of breast cancer.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":"120-130"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10201749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nano-based Therapeutics for Rheumatoid Arthritis: Recent Patents and Development.","authors":"Manish Makhija, Deeksha Manchanda, Manu Sharma","doi":"10.2174/1872210518666230905155459","DOIUrl":"10.2174/1872210518666230905155459","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease marked by inflammation of synovium and generation of autoantibodies. Bone and cartilage are frequently damaged along with weakening of tendons and ligaments resulting in disability. An effective RA treatment needs a multi-disciplinary approach which relies upon pathophysiology that is still partially understood. In RA patients, inflammation was induced by pro-inflammatory cytokines including IL-1, IL-6 & IL-10. The conventional dosage regimens for treating RA have drawbacks such as ineffectiveness, greater doses, frequent dosing, relatively expensive and serious adverse effects. To formulate an effective treatment plan for RA, research teams have recently focused on producing several nanoformulations containing anti-inflammatory APIs with an aim to target the inflamed area. Nanomedicines have recently gained popularity in the treatment of RA. Interestingly, unbelievable improvements have been observed in current years in diagnosis and management of RA utilizing nanotechnology. Various patents and clinical trial data have been reported in relevance to RA treatment.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":"56-75"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10199778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Efficient Suppression of EGFR and B-Raf mRNA Overexpression in the Lung of Benzo[a]pyrene-induced mice by Cationic Lipo-ATRA Nanoformulation.","authors":"Berlin Grace Viswanathan Mariammal, David Wilson Devarajan, Siddikuzzaman, Viswanathan Singaram, Ragavi Ravichandran, Guruvayoorappan Chandrasekharan, Kathirvelan Chinnadurai","doi":"10.2174/0118722105246143231016105620","DOIUrl":"10.2174/0118722105246143231016105620","url":null,"abstract":"<p><strong>Background: </strong>The molecular drug all-trans retinoic acid (ATRA) acts on cancer cells via different molecular pathways, but its poor bioavailability in cancer cells limits its potency. Recently few patents have been published for the development of liposome-based drug for enhanced action. This study was, therefore, carried out to analyse the oncogene expressions in the lung tissue of benzo[ a]pyrene (B[a]P)-induced mice and compare between free ATRA and cationic liposome nanoformulation (lipo-ATRA) treatments.</p><p><strong>Objective: </strong>This study was designed to analyse the changes in the expression levels of epidermal growth factor receptor (EGFR) and B-Raf in the lung tissues of B[a]P-induced mice during the cancer development stage itself and to find the suppressive effect of free ATRA and lipo-ATRA.</p><p><strong>Methods: </strong>Lung cancer was induced in mice by oral ingestion of 50mg/kg body weight B[a]P weekly twice for four consecutive weeks. Then, the mice were treated with free and lipo-ATRA (0.60 mg/kg) for 30 days via i.v injection. The EGFR and B-Raf gene expressions were analyzed in lung cells by reverse transcriptase polymerase chain reaction (RT-PCR) and quantitative polymerase chain reaction (qPCR).</p><p><strong>Results: </strong>The RT-PCR gene band density and the relative quantity (RQ) values from qPCR revealed both EGFR and B-Raf genes to be significantly overexpressed in B[a]P control mice while having very low or no expression in normal mice. This indicates that they function as oncogenes in B[a]P-induced lung carcinogenesis. The lipo-ATRA treatment has shown a highly significant increase in RQ values for both EGFR and BRaf when compared to the free ATRA treatment.</p><p><strong>Conclusion: </strong>The study results have revealed the cationic lipo-ATRA treatment to have enhanced the bioavailability of ATRA in lung tissue due to its significant suppression action on EGFR-mediated oncogenes' expressions. Furthermore, the EGFR and BRaf could be the molecular targets of ATRA action in lung carcinogenesis.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":"131-139"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71488000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanotheranostics: The Fabrication of Theranostics with Nanoparticles and their Application to Treat the Neurological Disorders.","authors":"Astha Singh, Aakriti Patel, Hema Chaudhary, Kiran Yadav, Neha Minocha","doi":"10.2174/1872210517666230718115651","DOIUrl":"10.2174/1872210517666230718115651","url":null,"abstract":"<p><strong>Background: </strong>Theranostics is a method that focuses on providing patient-centred care and is evolving as a targeted, safe, and effective pharmacotherapy. Nanotheranostics combines diagnosis and therapeutic modalities that bridge traditional treatment and personalised medicine. Theranostics provides novel ideas for nanotechnology. This review describes the current state of nanotechnology-based therapies used to treat neurological illnesses. Some patents on theranostics are also discussed in this review.</p><p><strong>Objective: </strong>This study aims to provide a more comprehensive review of the diagnosis and therapeutic properties of nanotheranostics, the present state of nanotechnology-based treatment of neurological disorders, and the future potential of theranostics.</p><p><strong>Methods: </strong>The phrase \"theranostics\" refers to a treatment strategy that integrates therapeutics and diagnostics to monitor treatment response and enhance drug efficacy and safety. Theranostics is a crucial component of personalised medicine and calls for significant advancements in predictive medicine. The term \"theranostics\" refers to a diagnosis that screens patients for potential adverse drug reactions and targets drug delivery depending on the test results. Theranostics treats neurological disorders (like brain tumours (glioma), Parkinson's disease, Alzheimer's disease, and neurovascular diseases). Many review articles on Google Scholar, PubMed, Google Patents, and Scopus were used to gather information for this review. Data acquired from many sources was compiled in this review to provide more information on theranostics.</p><p><strong>Results: </strong>The role of various nanocarrier systems as theranostic agents for neurological illnesses and the fabrication of nanomaterials for theranostics are discussed in this article after evaluating a substantial number of review articles.</p><p><strong>Conclusion: </strong>The distinctive intrinsic features of nanoparticles make them useful for functionalization and imaging. Theranostics in nuclear medicine include diagnostic imaging and therapy using the same molecule that is radiolabeled differently or the same medication at various doses. It is possible to determine if a patient will benefit from a given treatment by visualising potential targets. Targeted nuclear therapy has been shown to be beneficial in patients if chosen carefully and has a good safety profile.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":"17-34"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9886813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design Optimization and Evaluation of Patented Fast-Dissolving Oral Thin Film of Ambrisentan for the Treatment of Hypertension.","authors":"Abhishek Kanugo","doi":"10.2174/0118722105298163240823100003","DOIUrl":"https://doi.org/10.2174/0118722105298163240823100003","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular diseases, including hypertension, are the prominent source of death globally. High blood pressure is responsible for heart failure and also damages the vital organs of the body, which also creates mortality. The activation of the sympathetic nervous system in the primary sunrise period is a highly critical condition, and several persons have lost their tissue due to the unavailability of medicine at this time.</p><p><strong>Objective: </strong>The present research deals with the progress of fast-dissolving oral thin film (OTF) of Ambrisentan for the prevention and cure of hypertension.</p><p><strong>Methods: </strong>The OTF was established using the solvent casting method. The compatibility of Ambrisentan with film former HPMC E15 was checked with FTIR and DSC. The optimization was assessed using the design of the experiment using 32 Box-Behnken designs. The independent parameters were filmed former (X1: HPMC E15), plasticizer (X2: PEG 400), and super disintegrant (X3: cross povidone) and dependable parameters were disintegration time (Y1) and dissolution release (Y2).</p><p><strong>Results: </strong>The optimized batch F7 showed the least disintegration time (9 sec), folding endurance of (99), content uniformity (98.57 %), pH (6.4), and dissolved within 5 min. The scanning electron microscopy confirmed the evenness and smoothness of the film with a particle size of 10 μm. Patent related with OTF (Indian- 202321050359), US (11701339).</p><p><strong>Conclusion: </strong>The investigation indicated that fast dissolving oral thin film of Ambrisentan improves the solubility and therapeutic efficacy in the prevention and treatment of cardiovascular complications. The prompt release of Ambrisentan minimizes the mortality associated with heart attack and hypertension.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Solid to Fluid: Novel Approaches in Neuromorphic Engineering.","authors":"Daniil Nikitin, Hynek Biederman, Andrei Choukourov","doi":"10.2174/0118722105305259240919074119","DOIUrl":"https://doi.org/10.2174/0118722105305259240919074119","url":null,"abstract":"<p><p>Neuromorphic engineering is rapidly developing as an approach to mimicking processes in brains using artificial memristors, devices that change conductivity in response to the electrical field (resistive switching effect). Memristor-based neuromorphic systems can overcome the existing problems of slow and energy-inefficient computing that conventional processors face. In the Introduction, the basic principles of memristor operation and its applications are given. The history of switching in sandwich structures and granular metals is reviewed in the Historical Overview. Particular attention is paid to the fundamental articles from the pre-memristor era (the 1960s-70s), which demonstrated the first evidence of resistive switching and predicted the filamentary mechanism of switching. Multi-dimensionality in neuromorphic systems: Despite the powerful computational abilities of traditional memristor arrays, they cannot repeat many organizational characteristics of biological neural networks, i.e., their multi-dimensionality. This part reviews the unconventional nanowire- and nanoparticle-based neuromorphic systems that demonstrate incredible potential for use in reservoir computing due to the unique spiking change in conductance similar to firing in neurons. Liquid-based neuromorphic devices: The transition of neuromorphic systems from solid to liquid state broadens the possibilities for mimicking biological processes. In this section, ionic current memristors are reviewed and, the working principles of which bring us closer to the mechanisms of information transmittance in real synapses. Nanofluids: A novel direction in neuromorphic engineering linked to the application of nanofluids for the formation of reconfigurable nanoparticle networks with memristive properties is given in this section. The Conclusion t summarizes the bullet points of the Review and provides an outlook on the future of liquid-state neuromorphic systems.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Formulation Optimization and Evaluation of Patented Solid Lipid Nanoparticles of Ambrisentan for Pulmonary Arterial Hypertension.","authors":"Harshada Shewale, Abhishek Kanugo","doi":"10.2174/0118722105302631240816115638","DOIUrl":"https://doi.org/10.2174/0118722105302631240816115638","url":null,"abstract":"<p><strong>Background: </strong>Ambrisentan is a new endothelin receptor antagonist extensively used to manage pulmonary or pulmonary arterial hypertension.</p><p><strong>Objective: </strong>The therapeutic efficacy of Ambrisentan is limited due to its reduced solubility, higher log P (3.4), and thus less bioavailability. The recent investigation was concentrated on the improvement of solubility, and bioavailability of Ambrisentan for the therapy of hypertension via solid lipid nanoparticles (SLN) administered orally.</p><p><strong>Methods: </strong>XRD evaluated the compatibility of Ambrisentan with lipids with FTIR, DSC, and crystalline nature. The SLN was developed by High-pressure homogenization method. The Glyceryl monostearate and Tween 80 indicated the highest solubility, hence selected. The optimization was performed with Box-Behnken Design considering the concentration of GMS (X1), Tween 80 (X2), stirring speed (X3) as independent factors and particle size (Y1), entrapment efficiency (Y2) as dependent factors. The Patents on the SLN are Indian 202321053691, U.S. Patent, 10,973,798B2, U.S. Patent 10,251,960B2, U.S. Patent 2021/0069121A1 and U.S. Patent 2022/0151945A1.</p><p><strong>Results: </strong>The optimized batch F1 showed particle size (130 nm), ZP (-18.9 mV), and entrapment efficiency (85.73 %). The dual release pattern (prompt and sustained) was achieved with the SLNloaded Ambrisentan for about 24 hours. The lyophilized sample was subjected to SEM, which also revealed a spherical shape of a colloidal dispersion with a particle size of 126 nm. Hence, the F1 batch is highly recommended for solid oral delivery and also for the pilot-plant scale-up.</p><p><strong>Conclusion: </strong>A marked improvement in the solubility and dissolution of Ambrisentan was attained with the SLN. Moreover, the sustained delivery via the oral route enabled the patient's comfort, compliance, and therapeutic efficacy.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hybrid Nanophotonic Graphene Systems: A Transformative Innovation for Transdermal Drug Delivery.","authors":"Dilpreet Singh, Mandavi Pandey","doi":"10.2174/0118722105329862240919075834","DOIUrl":"10.2174/0118722105329862240919075834","url":null,"abstract":"<p><p>Transdermal Drug Delivery Systems (TDDSs) offer non-invasive administration and sustained drug release, enhancing patient compliance. However, the skin's natural barrier, particularly the stratum corneum, limits the effectiveness of TDDS for high molecular weight and hydrophilic substances. Innovations in material science, particularly hybrid nanophotonic graphene systems, present promising solutions. Nanophotonics generate localized photothermal effects to create microchannels in the skin, while graphene enhances permeability through its electrical and thermal conductivity. Hybrid nanophotonic systems, such as photonic crystals, plasmonic nanoparticles, metamaterials, quantum dots, nanowires, fiber optic nanosensors, and nanoantennas, offer precise control and real-time monitoring for applications in cancer therapy, chronic pain management, targeted drug delivery, and personalized medicine. This perspective examines the design, effectiveness, biocompatibility, and clinical implications of these hybrid systems, highlighting their potential to expand transdermal drug delivery and revolutionize treatment in personalized medicine. This particular formulation holds patentability, as supported by product patents that highlight the advancements in hybrid nanophotonic graphene systems for transdermal drug delivery.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}